Skip to content
OpenCapital
Get started

Eikon Therapeutics, Inc. EIKN Increase Decrease In Accrued Expenses And Other Current Liabilities

Other financials

Income statement

See full
Operating income-$87.3M-22.3%
Net income-$83.0M-21.6%
EPS (diluted)-$2.46+90.9%

Balance sheet

See full
Cash & equivalents$161.2M-21.2%
Total debt$254.8M—
Total equity$550.7M+186%
Total assets$850.8M—

Cash flow

See full
Operating cash flow-$89.8M-64.7%
CapEx$262.0K-98.8%
Free cash flow-$90.1M-17.1%

Valuation

See full
Market cap$521.35M—

Where this comes from

Reported directly by Eikon Therapeutics, Inc. in its filing.

Tagged under the XBRL concept eikn:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities.

The official record: Eikon Therapeutics, Inc. ’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Eikon Therapeutics, Inc. 's increase decrease in accrued expenses and other current liabilities?
Eikon Therapeutics, Inc. (EIKN) reported increase decrease in accrued expenses and other current liabilities of -$15.07M in Q1 2026.